Drug intelligence / Profile preview

Savi-CORD

Development stage: Unknown
Lead developer: Cell BioEngines
Modality: Cell Therapies
Administration: Intravenous

Overview

Savi-CORD is an expanded CD34+ hematopoietic cell therapy derived from banked allogeneic cord blood units, designed to enhance graft-versus-tumor activity in patients with acute leukemia and myelodysplastic syndromes who are candidates for hematopoietic stem cell transplantation. It uses a proprietary ex vivo expansion platform to generate “off‑the‑shelf” universal hematopoietic stem and progenitor cells aimed at improving engraftment and anti-leukemic effects in allogeneic HSCT settings. Developed by Cell BioEngines, Savi-CORD is being evaluated in Phase 1 clinical trials, with initial dosing reported in five patients.

Brand names: Savi-CORD
Other names: Savi CORD

Beyond the preview

Go deeper on Savi-CORD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Savi-CORD.

Explore the full profile